Atopic Dermatitis

Lisa Swanson, MD, FAAD, discusses how to balance the need for effective control of Alzheimer's disease symptoms with concerns about long-term safety, particularly when introducing new therapies.

Lisa Swanson, MD, FAAD, discusses how factors such as the safety profile, efficacy, age-appropriate dosing, and potential long-term effects of ruxolitinib cream would be crucial in determining its place in treatment for young children.

Lisa Swanson, MD, FAAD, discusses how caregivers play a crucial role in ensuring successful long-term AD management by providing daily support, monitoring treatment adherence, and offering emotional support, while dermatologists can better support them through education, clear communication, and collaborative care strategies.

Lisa Swanson, MD, FAAD, discusses how current treatment options for this age group fall short in terms of disease control, safety, and ease of use, while highlighting emerging options that promise better efficacy, fewer side effects, and greater convenience.

Lisa Swanson, MD, FAAD, discusses how pediatric atopic dermatitis (AD) treatment challenges include limited approved options, safety concerns, and adherence issues. Effective management requires balancing new therapies like Janus kinase (JAK) inhibitors with safety while supporting caregivers through education.

The cream contains barrier-repairing ingredients that may enhance self-healing and hydration in affected skin.

Use of the product showed positive changes in the skin’s hydration, lipid content, transepidermal water loss, and erythema.

Targeting type 2 cytokines with monoclonal antibodies has revolutionized treatment for inflammatory skin diseases, reducing symptoms and improving quality of life.

An expert panel of clinicians provided insights on first-line treatments, maintenance strategies, and flare management for AD.

The study identified 2 fungal profiles in AD patients, with 1 subgroup exhibiting distinct fungal dysbiosis.

A recent study highlights the need for ophthalmologic monitoring in pediatric dupilumab therapy.

The phase 1a study is a first in-human trial evaluating SYX-5219 for AD.

According to a survey, both patients and clinicians are unsatisfied with the current therapeutic landscape and are looking for options that better fulfill patient needs.

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis are particularly affected by social determinants of health, further impacting their outcomes.

By leveraging the innovative biomarker panels, clinicians can now offer more personalized and effective treatment options for psoriasis and AD.

Compared to placebo, there was a 70% reduction in IgE levels in children ages 0.5 to 6 after 16 weeks of therapy.

Ruxolitinib cream showlasting safety and efficacy in children with moderate to severe atopic dermatitis.

The study found half of the patients receiving once-monthly lebrikizumab achieved complete skin clearance at 3 years, with 87% maintaining near-clearance.

Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.

Panelists discuss the areas of research that need more attention in pediatric atopic dermatitis (AD) management, highlighting gaps in understanding the long-term effects of treatments, the genetic underpinnings of the disease, and strategies for improving early diagnosis and personalized care.

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

At AAD 2025, Raj Chovatiya, MD, PhD, MSCI, explored the role of social determinants in AD, HS, and PsO, emphasizing the need for improved clinical recognition and inclusive research.

Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream data presented at AAD 2025.

The ADORING 3 study demonstrated that tapinarof cream 1% maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

Raj Chovatiya, MD, PhD, MSCI, discusses how early-career dermatologists can gain the most benefit from this year’s annual meeting.